“Cardiac surgery has been a spectacularly innovative field of medicine,” says the abstract of a Mount Sinai School of Medicine grant proposal on the NIH RePORTER. “The introduction of major innovations and ongoing incremental change have extended survival and improved quality of life for many patients suffering from cardiac disease. A rapid pace of innovation requires a rigorous infrastructure for clinical evaluation that provides timely assessments of the value of new treatments.”
Science researchers at Mount Sinai School of Medicine were successful in their request seeking life science funding from the NIH. Earlier this year on July 17, 2013, the NIH awarded Mount Sinai School of Medicine’s Network for Cardiothoracic Surgical Investigations in Cardiovascular Medicine $7.6 million in life science research funding. The project leader, Dr. Annetine Gelijns, is president and chair of Health Evidence and Policy at Mount Sinai School of Medicine. The project’s abstract on NIH RePORTER provides more information on some of the challenges Mount Sinai researchers meet and what they will do to address them:
“The CTSN faces important challenges in designing and implementing trials, including the need to develop scientifically rigorous and feasible trials for evaluating surgical treatments for patients with cardiac disease that will serve as, and will be uniformly accepted as, the basis for treatment decisions. To meet these challenges we will provide leadership in the design of innovative exploratory clinical trials, exploiting our experience in designing novel clinical trials addressing specific needs not met by ‘off the shelf’ designs.”
Mount Sinai School of Medicine
Image courtesy of Wikimedia Commons
Lab suppliers interested in meeting researchers with available life science funding at Mount Sinai School of Medicine will find that the school is a potentially profitable market. In 2012, the NIH awarded Mount Sinai $178.7 million in life science research funding. In addition to receiving $178.7 million from the NIH, Mount Sinai also received $510,555 in life science funding from the NSF in 2012. For more funding information on Mount Sinai School of Medicine, please read our blog Research Funding Totals $179.2M at Mount Sinai.
Given this latest NIH grant awarded to Mount Sinai, it’s evident that Mount Sinai School of Medicine is a market with a great deal of potential for lab suppliers interested in marketing life science products. Biotechnology Calendar, Inc. invites all lab suppliers to meet researchers at our Mount Sinai BioResearch Product Faire™ Event on March 26th, 2014. In 2012, our Mount Sinai BioResearch Product Faire™ Event attracted 336 attendees. Of those who attended, 138 were purchasing agents, professors and post docs, and 41 were lab managers. The visitors came from 11 different research buildings and 56 departments around campus.
Biotechnology Calendar, Inc. is a science research events-planning and marketing company that organizes on-campus trade shows at top research institutions. If you are interested in meeting researchers at life science events at Mount Sinai or other life science events closer to home, we encourage you to view our 2014 calendar of events. For more information on our Mount Sinai BioResearch Product Faire™ Event, or to view more funding statistics for Mount Sinai School of Medicine, click on the button below.
